Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the UK's National Institute for Health and Care Excellence (NICE) has issued a Medtech innovation briefing (MIB) on the use of AnaConDa as an alternative to intravenous sedation in…
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that Susanne Andersson has been appointed new CFO and will take office during the first quarter of 2021. Susanne Andersson succeeds Maria Engström, who on her own initiative has chosen t…
Non-regulatory
Christer Ahlberg, CEO of Sedana Medical AB, has informed the company that he has sold 75 000 shares in Sedana Medical, representing approximately 0.33% of the total outstanding number of shares and 22.5% of his total shareholding in the company. Foll…
Regulatory
All-time-high sales and positive study result
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has signed a distribution agreement for sales in Australia and New Zeeland with the distributor Device Technologies. As the AnaConDa already has market approval in both…
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced a positive top line result for the company's pivotal phase III study, IsoConDa. The study reached its primary endpoint; to show that IsoConDa (isoflurane), administered with AnaConDa, is…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the medical device AnaConDa has received market approval in Saudi Arabia and that the company has signed distribution agreements for sales in the Middle East with Techno Orbits in S…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that it has signed agreements with distributors in Bulgaria, Cyprus, Greece, Slovakia and the Czech Republic. The agreements are part of the preparations ahead of the registration of the…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that all warrants in the company's incentive program 2017/21 have been exercised by the warrant holders, leading to an increase in the number of shares and votes in the company by 310,14…
Regulatory
Today, May 19, 2020, the annual general meeting of Sedana Medical AB (publ) (”Sedana Medical” or the "Company") was held in Stockholm. The general meeting resolved to adopt all of the board of directors’ and the nomination committee’s resolution prop…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that that the first patient has been included in SESAR, the world's largest multicenter study with AnaConDa to evaluate whether inhaled sedation via AnaConDa has lung-protective properti…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) meddelade idag att bolaget kommer att ge ekonomiskt stöd till en multinationell, observationsstudie där utfallet för patienter som får inhalationssedering jämförs med utfallet för patienter som får intr…
Regulatory
Hard work to meet the intensive care needs during COVID-19
Regulatory
The shareholders in Sedana Medical AB (publ), reg. no. 556670-2519, are hereby given notice to attend the annual general meeting on Tuesday 19 May 2020 at 4:00 p.m. (CEST) at Konferens Spårvagnshallarna, Birger Jarlsgatan 57 A in Stockholm. Registrat…
Regulatory
The nomination committee of Sedana Medical AB (publ) (SEDANA: FN Stockholm) has presented its resolution proposals for the annual general meeting 19 May 2020. The nomination committee’s proposals include, inter alia, re-election of all current ordina…
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company expects sales of approximately SEK 34 million in the first quarter of 2020, corresponding to growth of around 90 percent compared to the same period last year.
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company sees increased demand for AnaConDa as a result of the Covid-19 pandemic and so far, has had no significant supply chain disruptions. Sedana Medical forecasts a sales inc…
Non-regulatory
As a response to an increased amount of inquiries, Sedana Medical has decided to release an e-learning to educate healthcare professionals in the practical use of the AnaConDa.
Non-regulatory
Sedana Medical AB (publ) today announced the opening for researchers to apply for Sedana Medical Research Grant 2020. The grant creates a unique opportunity for the scientific community to increase knowledge of sedation therapies of critically ill pa…